News | September 21, 2008

GE Healthcare Demos Cardiac Heart Failure Imaging Tool

September 22, 2008 - GE Healthcare demonstrated a new diagnostic tool for heart failure called SyncTool by Syntermed on its GE Xeleris 2 workstations at the American Society of Nuclear Cardiology, Sept. 10-14, in Boston.

SyncTool software is designed to help to predict which heart failure patients will benefit from cardiac resynchronization therapy (CRT). SyncTool uses multiharmonic phase analysis (MHPA), a technology developed by Emory University medical scientists Ernest Garcia, Ph.D., and Ji Chen, Ph.D., and was licensed exclusively to Syntermed by Emory in June 2008. The software provides an automated analysis of LV function of conventional ECG-gated SPECT myocardial perfusion imaging.

Emory University announced it is exclusively licensing Emory Reconstruction Toolbox (ERTb) to Syntermed and the company will market ERTb software as ReconTools. ReconTools provide reconstructed data sets that can be analyzed by many quantitative platforms including Emory Cardiac Toolbox (ECTb), providing an integrated, complete software solution for myocardial perfusion SPECT imaging.

GE Healthcare is licensing SyncTool software as part of an Emory Cardiac Toolbox (ECTb) upgrade on all Xeleris 2 workstations. This software helps to predict which heart failure patients will benefit from cardiac resynchronization therapy (CRT).

Emory University announced it is exclusively licensing Emory Reconstruction Toolbox (ERTb) to Syntermed. The company will market ERTb software as ReconTools.

For more information: www.syntermed.com

Related Content

Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Overlay Init